This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stock

It's been a tough year for Novo Nordisk (NYSE: NVO) stock, to say the least. The company has undergone a change in CEO, its share price has been cut in half, and it has also slashed its guidance for the year due to rising competition in the GLP-1 drug market. Things have been spiraling for the stock, as it has been difficult to build up much of a bullish case for the company of late. It's easy, however, for the market to get overly bearish on a stock, crippling its valuation in the process. But Novo Nordi ...